http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IN-2014MN01484-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_835284fef6d8becc0032b30b06c99d24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6aba410fd8f85273a3a990f22e6bcb27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23910eaed62c33ab4e26b3a6d032fe7d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
| filingDate | 2011-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c61df8776acfd286a7e5656ce8f0830 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa56a0f59c367024ab5f3eedfc90041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a947a62f9a3394e760416fbe084f7f33 |
| publicationDate | 2015-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IN-2014MN01484-A |
| abstract | The invention relates to pharmaceutics and medicine and more specifically to compositions of a biologically active substance in particular supramolecular assemblies of acylated insulin oligopeptides for oral administration in the treatment of diabetes mellitus and complications thereof. The proposed system makes it possible using a single oral dose to maintain the level of glucose in the blood at a physiological level for 24 hours (super effect) and the ingredients of the system acquire resistance to enzymatic action have small dimensions and can be easily absorbed from the intestines. Essence of the invention: The principle active agents are in the form of a supramolecular composition namely an assembly consisting of acylated oligopeptide products of the enzymatic hydrolysis of insulin. The composition can be produced industrially in sufficient amounts on account of the availability of all of the ingredients of the composition. |
| priorityDate | 2011-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.